Innealta Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Innealta Capital’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-41	Closed	-$1.11K	–	1502
2024 Q2	$1.11K	Buy	+41	New	+$1.38K	﹤0.01%	1283

Other funds holding TARS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Innealta Capital's TARS Position: Q3 2024 in Review

Innealta Capital sold out of Tarsus Pharmaceuticals (TARS) in Q3 2024, closing a stake of 41 shares — an estimated $1.11K sold.

Innealta Capital first reported a position in TARS in Q2 2024 and held it in 1 quarter. The position peaked at $1.11K in Q2 2024. 162 funds tracked by Wall St. Rank hold TARS as of Q3 2024.

Innealta Capital reported no remaining Tarsus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 41 Tarsus Pharmaceuticals shares in Q3 2024, an estimated $1.11K.
Innealta Capital first reported a position in Tarsus Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Innealta Capital's Tarsus Pharmaceuticals position peaked at $1.11K in Q2 2024.
162 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.